drugset / Trial / NCT03968159
Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the efficacy and safety of adjunctive pimavanserin compared to placebo in subjects with major depressive disorder who have an inadequate response to antidepressant therapy
Timeline
- Start
- 2019-04-25
- Primary completion
- 2020-04-30
- Completion
- 2020-05-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pimavanserin | Small molecule | 34 mg | Oral |
Indications
No indication recorded.